As previously mentioned, GFRAL could also be targeted with an antagonist, to inhibit GDF15/GFRAL signalling, and for the treatment of different conditions such as cachexia, anorexia, or chemotherapy‐induced nausea and vomiting (CINV).[42, 43, 44] Despite previous attempts to treat obesity through GFRAL agonists, the studies on antagonists are lagging behind their agonist counterpart, and interest by pharmacological companies seem to be less pronounced. Here, GFRAL is linked to obesity disorder.